Systemic drug therapy for neuropathic pain

Detalhes bibliográficos
Autor(a) principal: Hennemann-Krause,Lilian
Data de Publicação: 2016
Outros Autores: Sredni,Sidney
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista Dor
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1806-00132016000500091
Resumo: ABSTRACT BACKGROUND AND OBJECTIVES: Neuropathic pain involves different etiologies, syndromes, pathophysiologic mechanisms and clinical symptoms, in addition to different treatment modalities. Most commonly used drugs to control neuropathic pain are antidepressants, anticonvulsants and opioids, and even so, they have moderate efficacy, with 50% pain relief in less than one third of patients. This study aimed at developing a guiding protocol for pharmacologic neuropathic pain management and also at introducing other drugs which may also relieve neuropathic pain. CONTENTS: This study has evaluated updated protocols of the Canadian Pain Society, the International Association for the Study of Pain, the European Federation of Neurological Societies and relevant references, being developed an algorithm for systemic drug therapy for neuropathic pain, made up of first line medications (tricyclic antidepressants, gabapentinoids and serotonin and norepinephrine reuptake inhibitors), second line medications (weak and strong opioids) and third line medications (selective serotonin reuptake inhibitors, dopamine and norepinephrine reuptake inhibitors and other anticonvulsants). Other drugs (anti-inflammatory, steroids and baclofen) and venous drug therapy (lidocaine and ketamine) used to control pain were also addressed. Major pharmacological actions, titration, interactions and relevant adverse effects of drugs indicated in the study were highlighted. CONCLUSION: Ideally, initial screening for pain control should be done with single therapy. If needed, other drugs may be combined to reach different pathophysiologic mechanisms and better neuropathic pain control. The algorithm should be a guide for analgesia, treatment should be tailored and, when indicated, combined with topic therapy and other non-pharmacological approaches.
id SBED-1_e7f7373eaa5074a8f7aee0b2c9672295
oai_identifier_str oai:scielo:S1806-00132016000500091
network_acronym_str SBED-1
network_name_str Revista Dor
repository_id_str
spelling Systemic drug therapy for neuropathic painAnticonvulsantsAntidepressantsChronic painNeuralgiaOpioidsPain managementABSTRACT BACKGROUND AND OBJECTIVES: Neuropathic pain involves different etiologies, syndromes, pathophysiologic mechanisms and clinical symptoms, in addition to different treatment modalities. Most commonly used drugs to control neuropathic pain are antidepressants, anticonvulsants and opioids, and even so, they have moderate efficacy, with 50% pain relief in less than one third of patients. This study aimed at developing a guiding protocol for pharmacologic neuropathic pain management and also at introducing other drugs which may also relieve neuropathic pain. CONTENTS: This study has evaluated updated protocols of the Canadian Pain Society, the International Association for the Study of Pain, the European Federation of Neurological Societies and relevant references, being developed an algorithm for systemic drug therapy for neuropathic pain, made up of first line medications (tricyclic antidepressants, gabapentinoids and serotonin and norepinephrine reuptake inhibitors), second line medications (weak and strong opioids) and third line medications (selective serotonin reuptake inhibitors, dopamine and norepinephrine reuptake inhibitors and other anticonvulsants). Other drugs (anti-inflammatory, steroids and baclofen) and venous drug therapy (lidocaine and ketamine) used to control pain were also addressed. Major pharmacological actions, titration, interactions and relevant adverse effects of drugs indicated in the study were highlighted. CONCLUSION: Ideally, initial screening for pain control should be done with single therapy. If needed, other drugs may be combined to reach different pathophysiologic mechanisms and better neuropathic pain control. The algorithm should be a guide for analgesia, treatment should be tailored and, when indicated, combined with topic therapy and other non-pharmacological approaches.Sociedade Brasileira para o Estudo da Dor2016-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1806-00132016000500091Revista Dor v.17 suppl.1 2016reponame:Revista Dorinstname:Sociedade Brasileira para o Estudo da Dor (SBED)instacron:SBED10.5935/1806-0013.20160057info:eu-repo/semantics/openAccessHennemann-Krause,LilianSredni,Sidneyeng2016-09-22T00:00:00Zoai:scielo:S1806-00132016000500091Revistahttps://www.scielo.br/j/rdor/ONGhttps://old.scielo.br/oai/scielo-oai.phpdor@dor.org.br||dor@dor.org.br2317-63931806-0013opendoar:2016-09-22T00:00Revista Dor - Sociedade Brasileira para o Estudo da Dor (SBED)false
dc.title.none.fl_str_mv Systemic drug therapy for neuropathic pain
title Systemic drug therapy for neuropathic pain
spellingShingle Systemic drug therapy for neuropathic pain
Hennemann-Krause,Lilian
Anticonvulsants
Antidepressants
Chronic pain
Neuralgia
Opioids
Pain management
title_short Systemic drug therapy for neuropathic pain
title_full Systemic drug therapy for neuropathic pain
title_fullStr Systemic drug therapy for neuropathic pain
title_full_unstemmed Systemic drug therapy for neuropathic pain
title_sort Systemic drug therapy for neuropathic pain
author Hennemann-Krause,Lilian
author_facet Hennemann-Krause,Lilian
Sredni,Sidney
author_role author
author2 Sredni,Sidney
author2_role author
dc.contributor.author.fl_str_mv Hennemann-Krause,Lilian
Sredni,Sidney
dc.subject.por.fl_str_mv Anticonvulsants
Antidepressants
Chronic pain
Neuralgia
Opioids
Pain management
topic Anticonvulsants
Antidepressants
Chronic pain
Neuralgia
Opioids
Pain management
description ABSTRACT BACKGROUND AND OBJECTIVES: Neuropathic pain involves different etiologies, syndromes, pathophysiologic mechanisms and clinical symptoms, in addition to different treatment modalities. Most commonly used drugs to control neuropathic pain are antidepressants, anticonvulsants and opioids, and even so, they have moderate efficacy, with 50% pain relief in less than one third of patients. This study aimed at developing a guiding protocol for pharmacologic neuropathic pain management and also at introducing other drugs which may also relieve neuropathic pain. CONTENTS: This study has evaluated updated protocols of the Canadian Pain Society, the International Association for the Study of Pain, the European Federation of Neurological Societies and relevant references, being developed an algorithm for systemic drug therapy for neuropathic pain, made up of first line medications (tricyclic antidepressants, gabapentinoids and serotonin and norepinephrine reuptake inhibitors), second line medications (weak and strong opioids) and third line medications (selective serotonin reuptake inhibitors, dopamine and norepinephrine reuptake inhibitors and other anticonvulsants). Other drugs (anti-inflammatory, steroids and baclofen) and venous drug therapy (lidocaine and ketamine) used to control pain were also addressed. Major pharmacological actions, titration, interactions and relevant adverse effects of drugs indicated in the study were highlighted. CONCLUSION: Ideally, initial screening for pain control should be done with single therapy. If needed, other drugs may be combined to reach different pathophysiologic mechanisms and better neuropathic pain control. The algorithm should be a guide for analgesia, treatment should be tailored and, when indicated, combined with topic therapy and other non-pharmacological approaches.
publishDate 2016
dc.date.none.fl_str_mv 2016-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1806-00132016000500091
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1806-00132016000500091
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.5935/1806-0013.20160057
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira para o Estudo da Dor
publisher.none.fl_str_mv Sociedade Brasileira para o Estudo da Dor
dc.source.none.fl_str_mv Revista Dor v.17 suppl.1 2016
reponame:Revista Dor
instname:Sociedade Brasileira para o Estudo da Dor (SBED)
instacron:SBED
instname_str Sociedade Brasileira para o Estudo da Dor (SBED)
instacron_str SBED
institution SBED
reponame_str Revista Dor
collection Revista Dor
repository.name.fl_str_mv Revista Dor - Sociedade Brasileira para o Estudo da Dor (SBED)
repository.mail.fl_str_mv dor@dor.org.br||dor@dor.org.br
_version_ 1752126255675736064